Indivior Pharmaceuticals (INDV) Cash & Current Investments (2021 - 2026)

Indivior Pharmaceuticals' Cash & Current Investments history runs 6 years deep, the most recent figure standing at $175.0 million for Q1 2026.

• On a quarterly basis, Cash & Current Investments fell 53.08% year-over-year to $175.0 million in Q1 2026; TTM through Mar 2026 was $175.0 million, a 53.08% decrease from a year earlier, with the FY2025 full-year figure at $195.0 million, down 39.06% from the prior year.
• Cash & Current Investments slipped to $175.0 million in Q1 2026 per INDV's latest filing, from $195.0 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $893.0 million in Q4 2022 and bottomed at $175.0 million in Q1 2026.
• The 5-year median for Cash & Current Investments is $391.5 million (2023), against an average of $415.1 million.
• Across the five-year window, Cash & Current Investments retreated 18.97% in 2022 and slumped 54.09% in 2023, its largest moves.
• Year by year, Cash & Current Investments stood at $893.0 million in 2022, then slumped by 54.09% to $410.0 million in 2023, then decreased by 21.95% to $320.0 million in 2024, then sank by 39.06% to $195.0 million in 2025, then dropped by 10.26% to $175.0 million in 2026.
• Per Business Quant, the three latest INDV Cash & Current Investments figures stand at $175.0 million (Q1 2026), $195.0 million (Q4 2025), and $445.0 million (Q3 2025).